Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS- 962212 in Healthy Subjects
NCT03197779 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS- 962212 in Healthy Subjects
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 18, 2013
- Completion date
- January 24, 2017
- Enrollment
- 691 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.